Long Acting Beta Agonists Antihistamines Corticosteroids Hormones Antineoplastics Micronized Non Micronized Inhalation Oral Topical Injection Ocular Eye Drop Salmeterol Xinafoate Formoterol Fumarate Dihydrate Indacaterol Maleate Azelastine Hydrochloride Budesonide Fluticasone Propionate Fluticasone Furoate Mometasone Furoate Mometasone Furoate Monohydrate Isoflupredone Acetate Ciclesonide Flunisolide Triamcinolone Triamcinolone Acetonide Triamcinolone Hexacetonide Fluocinolone Acetonide Fluocinonide Deflazacort Clobetasol Propionate Norethisterone Norethisterone Acetate Medroxyprogestrone Acetate Estramustine Sodium Phosphate Flutamide Danazol Exemestane
Product Category
(-) β2-agonists
◦ Salmeterol Xinafoate
◦ Formoterol Fumarate Dihydrate
◦ Indacaterol Maleate
Antihistamines (1)
Corticosteroids (15)
Hormones (3)
Antineoplastics (4)
Available Grades
Micronized (22)
Non Micronized (4)
Administration Route
Inhalation (11)
Oral (9)
Topical (5)
Injection (6)
Ocular (1)
Product Category : LABA (Long Acting Beta Agonists)
Chemical Name : (R)-5-[2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1H-quinolin-2-one maleate
General Information : Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
Administration Route : Inhalation
ATC Code : R03AC18
Related APIs : Fluticasone Furoate, Formoterol Fumarate, Salmeterol Xinafoate
: Under Development
Formula
C24H28N2O3.C4H4O4
CAS No.
753498-25-8
Molecular Weight
508.56 g/mol
Grade
Micronized